Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck & Co., Inc.

http://www.merck.com

Latest From Merck & Co., Inc.

COVID-19 Will Forever Change Workplace, But Not Necessarily For The Better, Merck’s Frazier Says

Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."

Coronavirus COVID-19 Leadership

And The UK's First 'Innovation Passport' Goes To... Merck's Rare Disease Drug Belzutifan

The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.

Europe United Kingdom

Merck & Co, Indian Firms On Tackling Supply Chain Risks And A Hijack

Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.

Commercial Coronavirus COVID-19

US FDA's Ebola Drug Approvals Showcase Efficiencies With Master Protocols

Agency approved Regeneron’s monoclonal antibody cocktail Inmazeb and Ridgeback’s mAB Ebanga on data from a multi-arm, adaptive trial in which several investigational agents were independently compared to a control group. Efficacy for both drugs was demonstrated on a mortality endpoint, with lingering uncertainties to be addressed through postmarketing studies.

Drug Review Profile Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abmaxis
    • Acacia Biosciences
    • Afferent Pharmaceuticals
    • ArQule, Inc.
    • Avecia Biologics Limited
    • Banyu Pharmaceutical Co., Ltd.
    • Calporta Therapeutics
    • cCAM Biotherapeutics Ltd.
    • Cubist Pharmaceuticals, Inc. (Adolor Corporation (ADLR)
    • Calixa Therapeutics, Inc.
    • Optimer Pharmaceuticals, Inc.
    • Trius Therapeutics, Inc.)
    • Idenix Pharmaceuticals, Inc.
    • Immune Design Corporation
    • Inspire Pharmaceuticals, Inc.
    • IOmet Pharma
    • iOnctura SA
    • Integrated Therapeutics Group
    • Merck Sharp & Dohme (MSD) Pharmaceuticals Pvt. Ltd.
    • MSD K.K. (Japan)
    • Nobilon International BV
    • Novacardia
    • OncoEthix SA
    • Organon BioSciences
    • Peloton Therapeutics, Inc.
    • Rigontec GmbH
    • Schering-Plough Corporation
    • SmartCells, Inc.
    • Tilos Therapeutics, Inc.
    • Vallee S.A.
    • Viralytics Limited (ASX:VLA)
    • Themis Biosciences GmbH
UsernamePublicRestriction

Register